Free Trial

89bio (ETNB) Competitors

$8.31
-0.04 (-0.48%)
(As of 04:27 PM ET)

ETNB vs. ICPT, ALBO, AKRO, TGTX, MRUS, XENE, BHVN, IDYA, FOLD, and RYTM

Should you be buying 89bio stock or one of its competitors? The main competitors of 89bio include Intercept Pharmaceuticals (ICPT), Albireo Pharma (ALBO), Akero Therapeutics (AKRO), TG Therapeutics (TGTX), Merus (MRUS), Xenon Pharmaceuticals (XENE), Biohaven (BHVN), IDEAYA Biosciences (IDYA), Amicus Therapeutics (FOLD), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "medical" sector.

89bio vs.

Intercept Pharmaceuticals (NASDAQ:ICPT) and 89bio (NASDAQ:ETNB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, community ranking, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

89bio has a net margin of 0.00% compared to 89bio's net margin of -19.39%. Intercept Pharmaceuticals' return on equity of -34.76% beat 89bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Intercept Pharmaceuticals-19.39% -77.48% -11.99%
89bio N/A -34.76%-31.05%

83.8% of Intercept Pharmaceuticals shares are owned by institutional investors. 6.2% of Intercept Pharmaceuticals shares are owned by insiders. Comparatively, 2.8% of 89bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Intercept Pharmaceuticals presently has a consensus price target of $19.00, indicating a potential upside of 0.00%. 89bio has a consensus price target of $26.67, indicating a potential upside of 231.26%. Given Intercept Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe 89bio is more favorable than Intercept Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intercept Pharmaceuticals
0 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
89bio
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.71

In the previous week, 89bio had 2 more articles in the media than Intercept Pharmaceuticals. MarketBeat recorded 2 mentions for 89bio and 0 mentions for Intercept Pharmaceuticals. Intercept Pharmaceuticals' average media sentiment score of 1.37 beat 89bio's score of 0.30 indicating that 89bio is being referred to more favorably in the news media.

Company Overall Sentiment
Intercept Pharmaceuticals Neutral
89bio Positive

Intercept Pharmaceuticals has higher revenue and earnings than 89bio. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intercept Pharmaceuticals$285.71M2.78$221.82M-$1.48-12.84
89bioN/AN/A-$142.19M-$2.01-4.12

Intercept Pharmaceuticals has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Comparatively, 89bio has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500.

Intercept Pharmaceuticals received 964 more outperform votes than 89bio when rated by MarketBeat users. Likewise, 71.98% of users gave Intercept Pharmaceuticals an outperform vote while only 63.75% of users gave 89bio an outperform vote.

CompanyUnderperformOutperform
Intercept PharmaceuticalsOutperform Votes
1066
71.98%
Underperform Votes
415
28.02%
89bioOutperform Votes
102
63.75%
Underperform Votes
58
36.25%

Summary

89bio beats Intercept Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ETNB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ETNB vs. The Competition

Metric89bioPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$815.57M$6.94B$5.06B$8.46B
Dividend YieldN/A2.85%5.25%3.97%
P/E Ratio-4.1211.08121.5015.44
Price / SalesN/A267.252,124.1978.77
Price / CashN/A32.1034.1233.62
Price / Book1.445.934.894.60
Net Income-$142.19M$143.37M$107.31M$214.44M
7 Day Performance-7.89%0.22%0.67%2.27%
1 Month Performance-2.70%8.30%9.02%8.69%
1 Year Performance-52.44%-2.74%8.21%3.90%

89bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ICPT
Intercept Pharmaceuticals
0.3399 of 5 stars
0.34 / 5 stars
$19.00
flat
$19.00
N/A$794.77M$285.71M-12.84341Analyst Forecast
ALBO
Albireo Pharma
0 of 5 stars
0.00 / 5 stars
$44.15
-0.2%
N/A+0.0%$913.91M$40.58M-6.57130Analyst Forecast
AKRO
Akero Therapeutics
4.3632 of 5 stars
4.36 / 5 stars
$26.76
-1.2%
$41.13
+53.7%
-38.8%$1.85BN/A-8.3658Positive News
Gap Down
TGTX
TG Therapeutics
3.9373 of 5 stars
3.94 / 5 stars
$21.00
-1.1%
$29.83
+42.1%
+1.8%$3.25B$289.33M91.30284News Coverage
Gap Down
MRUS
Merus
1.7786 of 5 stars
1.78 / 5 stars
$55.29
+0.9%
$80.90
+46.3%
+112.3%$3.24B$43.95M-19.9637Positive News
XENE
Xenon Pharmaceuticals
2.5076 of 5 stars
2.51 / 5 stars
$42.73
+2.5%
$59.11
+38.3%
+15.5%$3.22B$9.43M-15.77210Positive News
BHVN
Biohaven
2.94 of 5 stars
2.94 / 5 stars
$35.98
+3.7%
$54.71
+52.1%
+41.4%$3.18B$462.51M-5.27239Upcoming Earnings
Insider Buying
News Coverage
Positive News
IDYA
IDEAYA Biosciences
3.8201 of 5 stars
3.82 / 5 stars
$40.89
-0.5%
$52.92
+29.4%
+89.1%$3.09B$15.51M-20.34124
FOLD
Amicus Therapeutics
4.0982 of 5 stars
4.10 / 5 stars
$10.38
-2.5%
$17.57
+69.3%
-24.0%$3.07B$399.36M-21.18517Positive News
RYTM
Rhythm Pharmaceuticals
2.0352 of 5 stars
2.04 / 5 stars
$49.57
+0.6%
$54.33
+9.6%
+183.3%$3.02B$91.93M-10.71140News Coverage

Related Companies and Tools

This page (NASDAQ:ETNB) was last updated on 7/22/2024 by MarketBeat.com Staff

From Our Partners